Rockwell Medical reported that gross profit for the second quarter of 2015 increased 2.3% to $2.1 million, compared to the same quarter last year. Revenue for the quarter was 13 million, similar to last year. Research and development expenses for the second quarter were 0.9 million, compared to 0.8 million in 2014. Net loss was $2.5 million or $0.05 per share, compared to a net loss of $3.2 million or $0.08 per share in Q2 2014.

“Our focus and effort the last five months has been on performing the necessary work to launch Triferic commercially, as well as Calcitriol,” said Robert L. Chioini, chairman and CEO of Rockwell.

Read also: 2 new studies show benefits of Rockwell’s iron replacement therapy